Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric B Haura

Showing results (11-20 of 213) with videos related to

Pageof 22
Sort By:
Biochemical Pharmacology|June 4, 2010
Targeting epidermal growth factor receptor: central signaling kinase in lung cancerTakeshi Yoshida, Guolin Zhang, Eric B Haura
Nature Clinical Practice. Oncology|November 3, 2005
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancerEric B Haura, James Turkson, Richard Jove
Expert Review of Proteomics|September 26, 2018
Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeuticsM Boutchueng-Djidjou, Uwe Rix, Eric B Haura
Molecular Cancer Therapeutics|January 21, 2003
Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1Yihong Ma, W Douglas Cress, Eric B Haura
Methods in Molecular Medicine|November 1, 2002
Gene therapy for lung cancer. An introductionEric B Haura, Eduardo Sotomayor, Scott J Antonia
Nature Reviews. Clinical Oncology|September 30, 2009
Src kinases as therapeutic targets for cancerLori C Kim, Lanxi Song, Eric B Haura
Expert Opinion on Investigational Drugs|February 2, 2010
Dasatinib in solid tumorsLori C Kim, Uwe Rix, Eric B Haura
The American Journal of Bioethics : AJOB|April 16, 2014
The ethical imperative of risk disclosure in research: the answer is always yesGwendolyn P Quinn, Eric B Haura, Devin Murphy
Molecular Biotechnology|October 4, 2003
Gene therapy for lung cancerEric B Haura, Eduardo Sotomayor, Scott J Antonia
Expert Opinion on Therapeutic Targets|August 30, 2013
Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancerJae-Young Kim, Amer A Beg, Eric B Haura
Pageof 22

Showing results (11-20 of 213) with videos related to

Sort By:
Pageof 22
Biochemical Pharmacology|June 4, 2010
Targeting epidermal growth factor receptor: central signaling kinase in lung cancerTakeshi Yoshida, Guolin Zhang, Eric B Haura
Nature Clinical Practice. Oncology|November 3, 2005
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancerEric B Haura, James Turkson, Richard Jove
Expert Review of Proteomics|September 26, 2018
Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeuticsM Boutchueng-Djidjou, Uwe Rix, Eric B Haura
Molecular Cancer Therapeutics|January 21, 2003
Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1Yihong Ma, W Douglas Cress, Eric B Haura
Methods in Molecular Medicine|November 1, 2002
Gene therapy for lung cancer. An introductionEric B Haura, Eduardo Sotomayor, Scott J Antonia
Nature Reviews. Clinical Oncology|September 30, 2009
Src kinases as therapeutic targets for cancerLori C Kim, Lanxi Song, Eric B Haura
Expert Opinion on Investigational Drugs|February 2, 2010
Dasatinib in solid tumorsLori C Kim, Uwe Rix, Eric B Haura
The American Journal of Bioethics : AJOB|April 16, 2014
The ethical imperative of risk disclosure in research: the answer is always yesGwendolyn P Quinn, Eric B Haura, Devin Murphy
Molecular Biotechnology|October 4, 2003
Gene therapy for lung cancerEric B Haura, Eduardo Sotomayor, Scott J Antonia
Expert Opinion on Therapeutic Targets|August 30, 2013
Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancerJae-Young Kim, Amer A Beg, Eric B Haura
Pageof 22